Loading…
Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes
Listeria monocytogenes is a foodborne intracellular bacterial pathogen leading to human listeriosis. Despite a high mortality rate and increasing antibiotic resistance no clinically approved vaccine against Listeria is available. Attenuated Listeria strains offer protection and are tested as antitum...
Saved in:
Published in: | Nature communications 2022-10, Vol.13 (1), p.6075-17, Article 6075 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Listeria monocytogenes
is a foodborne intracellular bacterial pathogen leading to human listeriosis. Despite a high mortality rate and increasing antibiotic resistance no clinically approved vaccine against
Listeria
is available. Attenuated
Listeria
strains offer protection and are tested as antitumor vaccine vectors, but would benefit from a better knowledge on immunodominant vector antigens. To identify novel antigens, we screen for
Listeria
peptides presented on the surface of infected human cell lines by mass spectrometry-based immunopeptidomics. In between more than 15,000 human self-peptides, we detect 68
Listeria
immunopeptides from 42 different bacterial proteins, including several known antigens. Peptides presented on different cell lines are often derived from the same bacterial surface proteins, classifying these antigens as potential vaccine candidates. Encoding these highly presented antigens in lipid nanoparticle mRNA vaccine formulations results in specific CD8
+
T-cell responses and induces protection in vaccination challenge experiments in mice. Our results can serve as a starting point for the development of a clinical mRNA vaccine against
Listeria
and aid to improve attenuated
Listeria
vaccines and vectors, demonstrating the power of immunopeptidomics for next-generation bacterial vaccine development.
Currently, no approved vaccines for
Listeria monocytogenes
are available. Here, the authors use immunopeptidomics to map bacterial peptides presented on infected cells and identify antigens that, as mRNA vaccine, provide protection in mice. |
---|---|
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/s41467-022-33721-y |